|
1
|
Tan P and Yeoh KG: Genetics and molecular
pathogenesis of gastric adenocarcinoma. Gastroenterology.
149:1153–1162.e3. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Meyer HJ and Wilke H: Treatment strategies
in gastric cancer. Dtsch Arztebl Int. 108:698–705.
7062011.PubMed/NCBI
|
|
3
|
Saka M, Morita S, Fukagawa T and Katai H:
Present and future status of gastric cancer surgery. Jpn J Clin
Oncol. 41:307–313. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Giles RH, Peters DJ and Breuning MH:
Conjunction dysfunction: CBP/p300 in human disease. Trends Genet.
14:178–183. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Roth SY, Denu JM and Allis CD: Histone
acetyltransferases. Annu Rev Biochem. 70:81–120. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shiama N: The p300/CBP family: Integrating
signals with transcription factors and chromatin. Trends Cell Biol.
7:230–236. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Giordano A and Avantaggiati ML: p300 and
CBP: Partners for life and death. J Cell Physiol. 181:218–230.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan HM and La Thangue NB: p300/CBP
proteins: HATs for transcriptional bridges and scaffolds. J Cell
Sci. 114:2363–2373. 2001.PubMed/NCBI
|
|
9
|
Debes JD, Sebo TJ, Lohse CM, Murphy LM,
Haugen DA and Tindall DJ: p300 in prostate cancer proliferation and
progression. Cancer Res. 63:7638–7640. 2003.PubMed/NCBI
|
|
10
|
Linja MJ, Porkka KP, Kang Z, Savinainen
KJ, Jänne OA, Tammela TL, Vessella RL, Palvimo JJ and Visakorpi T:
Expression of androgen receptor coregulators in prostate cancer.
Clin Cancer Res. 10:1032–1040. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Santer FR, Höschele PP, Oh SJ, Erb HH,
Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA and Culig Z:
Inhibition of the acetyltransferases p300 and CBP reveals a
targetable function for p300 in the survival and invasion pathways
of prostate cancer cell lines. Mol Cancer Ther. 10:1644–1655. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Iyer NG, Chin SF, Ozdag H, Daigo Y, Hu DE,
Cariati M, Brindle K, Aparicio S and Caldas C: p300 regulates
p53-dependent apoptosis after DNA damage in colorectal cancer cells
by modulation of PUMA/p21 levels. Proc Natl Acad Sci USA.
101:7386–7391. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin WM, Baker AC, Beroukhim R, Winckler W,
Feng W, Marmion JM, Laine E, Greulich H, Tseng H, Gates C, et al:
Modeling genomic diversity and tumor dependency in malignant
melanoma. Cancer Res. 68:664–673. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garraway LA, Widlund HR, Rubin MA, Getz G,
Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J,
et al: Integrative genomic analyses identify MITF as a lineage
survival oncogene amplified in malignant melanoma. Nature.
436:117–122. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sato S, Roberts K, Gambino G, Cook A,
Kouzarides T and Goding CR: CBP/p300 as a co-factor for the
Microphthalmia transcription factor. Oncogene. 14:3083–3092. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yajima I, Kumasaka MY, Thang ND, Goto Y,
Takeda K, Iida M, Ohgami N, Tamura H, Yamanoshita O, Kawamoto Y, et
al: Molecular Network associated with MITF in skin melanoma
development and progression. J Skin Cancer. 2011:7301702011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Paladino D, Yue P, Furuya H, Acoba J,
Rosser CJ and Turkson J: A novel nuclear Src and p300 signaling
axis controls migratory and invasive behavior in pancreatic cancer.
Oncotarget. 7:7253–7267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han RF, Ji X, Dong XG, Xiao RJ, Liu YP,
Xiong J and Zhang QP: An epigenetic mechanism underlying
doxorubicin induced EMT in the human BGC-823 gastric cancer cell.
Asian Pac J Cancer Prev. 15:4271–4274. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gao XN, Lin J, Ning QY, Gao L, Yao YS,
Zhou JH, Li YH, Wang LL and Yu L: A histone acetyltransferase p300
inhibitor C646 induces cell cycle arrest and apoptosis selectively
in AML1-ETO-positive AML cells. PLoS One. 8:e554812013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gu ML, Wang YM, Zhou XX, Yao HP, Zheng S,
Xiang Z and Ji F: An inhibitor of the acetyltransferases CBP/p300
exerts antineoplastic effects on gastrointestinal stromal tumor
cells. Oncol Rep. 36:2763–2770. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang Y, Gu ML, Zhou XX, Ma H, Yao HP and
Ji F: Altered expression of ETV1 and its contribution to
tumorigenic phenotypes in gastrointestinal stromal tumors. Oncol
Rep. 32:927–934. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Friedmann DR and Marmorstein R: Structure
and mechanism of non-histone protein acetyltransferase enzymes.
FEBS J. 280:5570–5581. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang L, Gural A, Sun XJ, Zhao X, Perna F,
Huang G, Hatlen MA, Vu L, Liu F, Xu H, et al: The leukemogenicity
of AML1-ETO is dependent on site-specific lysine acetylation.
Science. 333:765–769. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wu Y, Yao X, Zhu M, Qian H, Jiang L, Lan
T, Wu M, Pang J and Chen Y: PKG II reverses HGF-triggered cellular
activities by phosphorylating serine 985 of c-Met in gastric cancer
cells. Oncotarget. 7:34190–34200. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Marano L, Chiari R, Fabozzi A, De Vita F,
Boccardi V, Roviello G, Petrioli R, Marrelli D, Roviello F and
Patriti A: c-Met targeting in advanced gastric cancer: An open
challenge. Cancer Lett. 365:30–36. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fuse N, Kuboki Y, Kuwata T, Nishina T,
Kadowaki S, Shinozaki E, Machida N, Yuki S, Ooki A, Kajiura S, et
al: Prognostic impact of HER2, EGFR, and c-MET status on overall
survival of advanced gastric cancer patients. Gastric Cancer.
19:183–191. 2016. View Article : Google Scholar
|
|
27
|
Katsumoto T, Yoshida N and Kitabayashi I:
Roles of the histone acetyltransferase monocytic leukemia zinc
finger protein in normal and malignant hematopoiesis. Cancer Sci.
99:1523–1527. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lu YF, Zhang L, Waye MM, Fu WM and Zhang
JF: MiR-218 mediates tumorigenesis and metastasis: Perspectives and
implications. Exp Cell Res. 334:173–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li S, Zhang H, Wang X, Qu Y, Duan J, Liu
R, Deng T, Ning T, Zhang L, Bai M, et al: Direct targeting of HGF
by miR-16 regulates proliferation and migration in gastric cancer.
Tumour Biol. 37:15175–15183. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei B, Huang QY, Huang SR, Mai W and Zhong
XG: MicroRNA-34a attenuates the proliferation, invasion and
metastasis of gastric cancer cells via downregulation of MET. Mol
Med Rep. 12:5255–5261. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Han C, Zhou Y, An Q, Li F, Li D, Zhang X,
Yu Z, Zheng L, Duan Z and Kan Q: MicroRNA-1 (miR-1) inhibits
gastric cancer cell proliferation and migration by targeting MET.
Tumour Biol. 36:6715–6723. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ji Z, Su J, Liu C, Wang H, Huang D and
Zhou X: Integrating genomics and proteomics data to predict drug
effects using binary linear programming. PLoS One. 9:e1027982014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kholodenko BN, Demin OV, Moehren G and
Hoek JB: Quantification of short term signaling by the epidermal
growth factor receptor. J Biol Chem. 274:30169–30181. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee HR, Mitra J, Lee S, Gao SJ, Oh TK, Kim
MH, Ha T and Jung JU: Kaposi's sarcoma-associated herpesvirus viral
interferon regulatory factor 4 (vIRF4) perturbs the G1-S cell cycle
progression via deregulation of the cyclin D1 gene. J Virol.
90:1139–1143. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gao H, Wu B, Le Y and Zhu Z: Homeobox
protein VentX induces p53-independent apoptosis in cancer cells.
Oncotarget. 7:39719–39729. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
He X, Wang L, Riedel H, Wang K, Yang Y,
Dinu CZ and Rojanasakul Y: Mesothelin promotes
epithelial-to-mesenchymal transition and tumorigenicity of human
lung cancer and mesothelioma cells. Mol Cancer. 16:632017.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ito T, Kajino K, Abe M, Sato K, Maekawa H,
Sakurada M, Orita H, Wada R, Kajiyama Y and Hino O: ERC/mesothelin
is expressed in human gastric cancer tissues and cell lines. Oncol
Rep. 31:27–33. 2014. View Article : Google Scholar
|
|
38
|
Einama T, Homma S, Kamachi H, Kawamata F,
Takahashi K, Takahashi N, Taniguchi M, Kamiyama T, Furukawa H,
Matsuno Y, et al: Luminal membrane expression of mesothelin is a
prominent poor prognostic factor for gastric cancer. Br J Cancer.
107:137–142. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Baba K, Ishigami S, Arigami T, Uenosono Y,
Okumura H, Matsumoto M, Kurahara H, Uchikado Y, Kita Y, Kijima Y,
et al: Mesothelin expression correlates with prolonged patient
survival in gastric cancer. J Surg Oncol. 105:195–199. 2012.
View Article : Google Scholar
|
